木瓜直播

Mark Fuerst

Mark Fuerst

Authors >

Mark Fuerst

Mark Fuerst received a BS degree in biology at Dickinson College and an MA in Journalism at the University of Missouri-Columbia. He currently lives in East Hampton, NY, where you鈥檒l find him playing golf, practicing tai chi, and walking his dog on the beach.

Connect:

email image

Latest from Mark Fuerst

Julia Lai-Kwon, MBBS, on Integrating PRO Measurements in Advanced Cancer Care

Symptom monitoring using PROs in routine care is a worthwhile investment for gynecologic and other cancer patients

Pedro Ramirez on Open vs Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer

"Unexpected findings" from final results of international open-label randomized non-inferiority trial

Brian Slomovitz on How Targeted Therapies Are Transforming GYN Cancer Care

"The field is changing so much, almost on a daily or weekly basis"

Andreas Obermair, MD, on Decisions on Surgical Management of Gynecological Cancers

Minimally invasive surgery and fertility preservation are key elements in gynecologic cancers.

Ishani Ganguli, MD, on Healthcare 'Contact Days' Among Older Survivors of GYN and Other Cancers

Study showed doctors may be missing opportunities for better coordination of care

Precision Radiotherapy Ups Response in Locally Advanced Vulvar Cancer

Shows IMRT plus adding gemcitabine to cisplatin is appropriate when surgery is not possible

Ann Klopp, MD, PhD, on Why Cisplatin Should Not Be Added to RT for Certain Recurrent Endometrial Cancers

Chemotherapy increased toxicity and did not improve PFS, study showed

Jill Kolesar, PharmD, on Expanding Germline Testing for Gynecological Cancers

Research-grade germline sequencing proved feasible, with clinical implications for both patients and family members

Phillip Febbo on Recommendations for Equitable Implementation of Liquid Biopsy

"Call to action" for ovarian and other cancer patients to have access to ctDNA-detecting tests

A Look at Trabectedin Monotherapy for Recurrent Ovarian Cancer

Prospective, open-label phase III study in BRCA-mutated or BRCAness phenotype

1